Ockham Announces Formation of Scientific Board of AdvisorsOckham is pleased to announce the formation of its Scientific Board of Advisors.
By: Kelly Morrison CONTACT: Michael J. Baker Vice-President, Business Development Phone: +1 919 653 6081 E-mail: mbaker@ockham.com Ockham Announces Formation of Scientific Board of Advisors Cary, NC, February 8, 2011 – Ockham, a Global Contract Research (CRO) and Functional Service Provider (FSP) organization (OckhamCROTM) The Board of Advisors is comprised of three distinguished medical professionals with robust oncology background, who will provide direction and insight for Ockham as it continues to expedite the oncology drug development process. “As we continue to provide additional value to our clients, I am honored to have three distinguished professionals with significant experience join our team. Everyday we try to improve what we can do for our clients, and what we can do for our company. Establishing the Scientific Board of Advisors is another step Ockham is taking in the fight against cancer and other diseases,” said James Baker, CEO of Ockham. Members of the Scientific Board of Advisors include: Ed Schnipper, M.D. - Over the past 20 years, Dr. Schnipper has been responsible for numerous clinical trial programs that resulted in successful development, approval and commercial growth for pharmaceutical products in oncology and other therapeutic areas. Dr. Schnipper has led development for several successful products including the first generation nanoparticle drug Doxil, as well as Ditropan XL, Viadur and Concerta. Previously, he was Vice President of Clinical Development at ALZA, Senior Vice President and Medical Director at SEQUUS and held various senior clinical positions at Hoffmann-La Roche. Dr. Schnipper earned his M.D. from Georgetown University School of Medicine and completed fellowships in hematology at New York University and in medical oncology at Memorial Sloan-Kettering Cancer Center. William McCulloch, M.D. - Since 1984, Dr. McCulloch has served as a senior R&D executive in a variety of large and small international companies, applying his extensive experience in developing and commercializing technologies. Prior to that, he practiced medicine for seven years in the U.K., including post-graduate training in oncology, hematology, and internal medicine. He is Founder and President of Alba BioPharm Advisors, based in Scotland. Dr. McCulloch’s expertise includes non-clinical and clinical development, regulatory and medical affairs, licensing and sales force training, with a focus in oncology and serious infectious diseases. He is also experienced in all phases of drug and technology development, and has been directly involved in filing INDs and NDAs, securing Orphan Drug status for compounds and obtaining SBIR and other grant funding for his projects. Dr. Thomas F. Pajak - Dr. Thomas F. Pajak was instrumental in the formation of the Radiation Therapy Oncology Group (RTOG), and served as lead statistician for over 23 years. Dr. Pajak has been involved in all aspects of phase I-III clinical trials, including design, conduct, analyses and reporting. His primary focus has been in head and neck cancer clinical trials; however, he has collaborated on trials for lung, gastrointestinal, prostate and brain tumors. Dr. Pajak received his doctoral degree from State University of New York at Buffalo. While in the program, he worked as a statistical intern in the Southwest Oncology Group Statistical Center at M.D. Anderson Cancer Hospital. About the Company: Ockham is a leading global CRO and FSP organization, supplemented by a robust traditional sourcing component, founded in 1986. The company offers a full range of clinical research services for Phase I-IV clinical trials in oncology, as well as other therapeutic areas. Ockham provides its clients with a combination of medical and technical expertise within their tightly controlled clinical studies. Ockham is headquartered in Cary, North Carolina with satellite offices strategically placed around the United States, India and the United Kingdom to serve global customers and operations. For more information about Ockham, visit www.ockham.com. # # # Ockham is a leading global CRO and FSP organization, supplemented by a robust traditional sourcing component, founded in 1986, with a focus in oncology. End
|
|
